Rapidly progressive glomerulonephritis pathophysiology

Jump to navigation Jump to search

Rapidly progressive glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rapidly progressive glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray Findings

CT-scan Findings

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Rapidly progressive glomerulonephritis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rapidly progressive glomerulonephritis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rapidly progressive glomerulonephritis pathophysiology

CDC on Rapidly progressive glomerulonephritis pathophysiology

Rapidly progressive glomerulonephritis pathophysiology in the news

Blogs on Rapidly progressive glomerulonephritis pathophysiology

Directions to Hospitals Treating Rapidly progressive glomerulonephritis

Risk calculators and risk factors for Rapidly progressive glomerulonephritis pathophysiology

.Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Jogeet Singh Sekhon, M.D. [2] Syed Ahsan Hussain, M.D.[3]

Overview

Rapidly progressive glomerulonephritis is a disease of the kidney in which the renal function deteriorates in a few days. Atleast 50% reduction in GFR occurs in RPGN in a few days to weeks. RPGN occurs from severe and fast damage to the GBM which results in crescent formation, the main pathological finding in RPGN. Injury can occur by anti GBM antibodies-type I RPGN, Immune complex- type II RPGN or pauci immune RPGN(ANCAs)-type III RPGN. Crescents are present in the Bowmans space. Light, immunofluoresnce and electron microscopy are used to diagnose RPGN.

Pathophysiology

Anatomy

Renal corpuscle. (Source: [Michal Komorniczak (Poland)[CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0)], from Wikimedia Commons])
Alveolar wall ([By Cruithne9 [CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0)], from Wikimedia Commons])


The key for the renal corpuscle figure is: A – Renal corpuscle, B – Proximal tubule, C – Distal convoluted tubule, D – Juxtaglomerular apparatus, 1. Basement membrane (Basal lamina), 2. Bowman's capsule – parietal layer, 3. Bowman's capsule – visceral layer, 3a. Pedicels (Foot processes from podocytes), 3b. Podocyte, 4. Bowman's space (urinary space), 5a. Mesangium – Intraglomerular cell, 5b. Mesangium – Extraglomerular cell, 6. Granular cells (Juxtaglomerular cells), 7. Macula densa, 8. Myocytes (smooth muscle), 9. Afferent arteriole, 10. Glomerulus Capillaries, 11. Efferent arteriole.

Pathogenesis

  • Rapidly progressive glomerulonephritis is a disease of the kidney in which the renal function deteriorates in a few days[1][2].
  • Atleast 50% reduction in GFR occurs in RPGN in a few days to weeks.
  • RPGN occurs from severe and fast damage to the GBM which results in crescent formation, the main pathological finding in RPGN.
  • The injury to GBM can be caused by multiple factors.
  • Crescent formation is the major pathological finding.
  • In some cases crescents might be absent.
Cresent formation
Glomerular injury
  • Injury to the glomerulus is the initiating factor for crescent formation.
  • Injury can occur by the following.
  1. Anti GBM antibodies-Type I RPGN
  • These are autoantibodies that cross react with type IV collagen of the GBM.
  • These can be produced due to genetic causes such as in Goodpasture syndrome or they can be produced after viral URTI or cigarette smoking.
  • These autoantibodies react with the GBM resulting in IgG deposition over the GBM.
  • The IgG activates helper T cells that attract the inflammatory mediators to the GBM damaging the glomeruli[7].
  • This damage causes leakage of cells and inflammatory mediators resulting in crescent formation.
  • The anti GBM antibodies can affect the lungs as well as in Goodpasture syndrome resulting in glomerular necrosis and pulmonary haemorrhages.

2. Immune complex- Type II RPGN

  • Immune complexes are formed in certain infections, connective tissue diseases, side effects of some drugs and in some myeloproliferative disorders[8].
  • These immune complexes are deposited over the GBM.
  • The immune complexes activate the complement system which sets off the inflammatory process.
  • The complement cascade is activated, attracting inflammatory cells and mediators to the GBM.
  • The serum levels of c3 and c4 fall down and is an indicator of immune complex mediated glomerular injury.

3. Pauci immune RPGN-Type III RPGN

Associated Conditions

Consitions associated with membranous glomerulonephritis include:[15]

Gross pathology

Microscopic pathology

Histopathology

Microscopic findings of RPGN Source:By Nephron - Own work[18]

Immunoflourescence

  • In type I RPGN- diffuse and linear deposition of IgG along the GBM.
  • In ttype II RPGN- diffuse and irregular deposition of IgG and C3 in the mesangial matrix.
  • In type III RPGN- no finding.

Electron microscopy

  • In type I and type III, no electron dense deposits are seen.
  • In type II RPGN, subepithelial electron dense deposits indiacting the presence of immune complexes are seen.

Genetics

People with HLA DP1,DQ and DRB4 are more susceptible to develop RPGN[19]. {{#ev:youtube|CqSyj4cVZPE}}

References

  1. Couser WG (1988). "Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy". Am J Kidney Dis. 11 (6): 449–64. PMID 3287904.
  2. 2.0 2.1 Couser WG (1998). "Pathogenesis of glomerular damage in glomerulonephritis". Nephrol Dial Transplant. 13 Suppl 1: 10–5. PMID 9507491.
  3. Roy S, Murphy WM, Arant BS (1981). "Poststreptococcal crescenteric glomerulonephritis in children: comparison of quintuple therapy versus supportive care". J Pediatr. 98 (3): 403–10. PMID 7205449.
  4. Atkins RC, Nikolic-Paterson DJ, Song Q, Lan HY (1996). "Modulators of crescentic glomerulonephritis". J Am Soc Nephrol. 7 (11): 2271–8. PMID 8959617.
  5. Bariéty J, Bruneval P, Meyrier A, Mandet C, Hill G, Jacquot C (2005). "Podocyte involvement in human immune crescentic glomerulonephritis". Kidney Int. 68 (3): 1109–19. doi:10.1111/j.1523-1755.2005.00503.x. PMID 16105041.
  6. Tipping PG, Timoshanko J (2005). "Contributions of intrinsic renal cells to crescentic glomerulonephritis". Nephron Exp Nephrol. 101 (4): e173–8. doi:10.1159/000088165. PMID 16155400.
  7. Huang XR, Tipping PG, Apostolopoulos J, Oettinger C, D'Souza M, Milton G; et al. (1997). "Mechanisms of T cell-induced glomerular injury in anti-glomerular basement membrane (GBM) glomerulonephritis in rats". Clin Exp Immunol. 109 (1): 134–42. PMC 1904710. PMID 9218836.
  8. Izzedine H, Camous L, Deray G (2007). "New insight on crescentic glomerulonephritis". Nephrol Dial Transplant. 22 (5): 1480–1. doi:10.1093/ndt/gfl742. PMID 17164315.
  9. "Chapter 10: Immunoglobulin A nephropathy". Kidney Int Suppl (2011). 2 (2): 209–217. 2012. doi:10.1038/kisup.2012.23. PMC 4089745. PMID 25018935.
  10. Heeringa P, Brouwer E, Klok PA, Huitema MG, van den Born J, Weening JJ; et al. (1996). "Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat". Am J Pathol. 149 (5): 1695–706. PMC 1865281. PMID 8909258.
  11. Yang G, Tang Z, Chen Y, Zeng C, Chen H, Liu Z; et al. (2005). "Antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with anti-GBM crescentic glomerulonephritis". Clin Nephrol. 63 (6): 423–8. PMID 15960143.
  12. de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, Jayne DR, Gaskin G, Rasmussen N; et al. (2006). "Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement". J Am Soc Nephrol. 17 (8): 2264–74. doi:10.1681/ASN.2005080870. PMID 16825335.
  13. Bomback AS, Appel GB, Radhakrishnan J, Shirazian S, Herlitz LC, Stokes B; et al. (2011). "ANCA-associated glomerulonephritis in the very elderly". Kidney Int. 79 (7): 757–64. doi:10.1038/ki.2010.489. PMID 21160463.
  14. Chen M, Yu F, Wang SX, Zou WZ, Zhao MH, Wang HY (2007). "Antineutrophil cytoplasmic autoantibody-negative Pauci-immune crescentic glomerulonephritis". J Am Soc Nephrol. 18 (2): 599–605. doi:10.1681/ASN.2006091021. PMID 17215440.
  15. Wasserstein AG (April 1997). "Membranous glomerulonephritis". J. Am. Soc. Nephrol. 8 (4): 664–74. PMID 10495797.
  16. Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K; et al. (2010). "Histopathologic classification of ANCA-associated glomerulonephritis". J Am Soc Nephrol. 21 (10): 1628–36. doi:10.1681/ASN.2010050477. PMID 20616173.
  17. Bonsib SM (1988). "Glomerular basement membrane necrosis and crescent organization". Kidney Int. 33 (5): 966–74. PMID 3392885.
  18. https://commons.wikimedia.org/w/index.php?curid=17591464
  19. Jagiello P, Gross WL, Epplen JT (2005). "Complex genetics of Wegener granulomatosis". Autoimmun Rev. 4 (1): 42–7. doi:10.1016/j.autrev.2004.06.003. PMID 15652778.

Template:WH Template:WS